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Abstract
Background: The hepatitis C virus (HCV) is one of the major risk factors for the development of hepatocellular carcinoma
(HCC). Nevertheless, transgenic mice which express the whole HCV polyprotein (HCV-Tg) do not develop HCC. Whereas
chronic HCV infection causes inflammation in patients, in HCV-Tg mice, the host immune reaction against viral proteins is
lacking. We aimed to test the role of HCV proteins in HCC development on the background of chronic inflammation in vivo.
Methodology/Principal Findings: We crossed HCV-Tg mice that do not develop HCC with the Mdr2-knockout (Mdr2-KO)
mice which develop inflammation-associated HCC, to generate Mdr2-KO/HCV-Tg mice. We studied the effect of the HCV
transgene on tumor incidence, hepatocyte mitosis and apoptosis, and investigated the potential contributing factors for the
generated phenotype by gene expression and protein analyses. The Mdr2-KO/HCV-Tg females from the N2 generation of
this breeding (having 75% of the FVB/N genome and 25% of the C57BL/6 genome) produced significantly larger tumors in
comparison with Mdr2-KO mice. In parallel, the Mdr2-KO/HCV-Tg females had an enhanced inflammatory gene expression
signature. However, in the N7 generation (having 99.2% of the FVB/N genome and 0.8% of the C57BL/6 genome) there was
no difference in tumor development between Mdr2-KO/HCV-Tg and Mdr2-KO animals of both sexes. The HCV transgene
was similarly expressed in the livers of Mdr2-KO/HCV-Tg females of both generations, as revealed by detection of the HCV
transcript and the core protein.
Conclusion: These findings suggest that the HCV transgene accelerated inflammation-associated hepatocarcinogenesis in a
host genetic background-dependent manner.
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Introduction
Hepatocellular carcinoma (HCC) is a significant health care
burden worldwide, and chronic inflammation is a major risk factor
for the development of HCC. The hepatitis C virus (HCV) is one
of the major etiological HCC agents: it induces chronic liver
inflammation and is responsible for the increased incidence of
HCC in the developed world [1]. Although multiple cell culture
models demonstrated oncogenic potential of several HCV
proteins, most transgenic mouse models expressing these proteins
did not develop HCC [2]. Furthermore, non infectious metabolic
conditions causing chronic hepatitis also expose humans to an
increased risk of developing HCC. Thus, determinants of HCC
development on the background of chronic inflammation could be
attributed to genetic/gender background, pathogen-derived or
environmentally-dependent factors [3–5]. The aim of this study is
to investigate the interplay between the factors contributing to the
development of HCC in a mouse model expressing HCV proteins.
The previously generated HCV transgenic (HCV-Tg) mouse
models produced inconsistent results concerning the role of HCV
proteins in HCC development. Only one model that expressed the
HCV core protein developed HCC with high incidence [6], and
two models that expressed the HCV core together with E1 and E2
proteins developed HCC with very low incidence [7,8]. However,
other models containing similar transgenes, albeit produced in
other laboratories, did not develop HCC [2]. Two groups created
HCV-Tg mice expressing the whole HCV polyprotein [7,9],
however, none of these models are developing HCC (although in
one model, HCC development was reported [7], this phenotype
disappeared in the progeny throughout the next generations [10]).
In transgenic animals, there is no inflammatory reaction against
proteins expressed by a transgene, whereas in HCV-infected
patients, the liver is inflamed. On the other hand, genetic models
with chronic liver inflammation develop HCC at a high rate [11–
13]. We and others have reported the importance of inflammatory
mediators in HCC development [14–17].
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accelerate inflammation-associated liver carcinogenesis, and to
identify and characterize the signaling pathways most likely to be
affected, we crossed one of the existing HCV-Tg models, which
produced detectable levels of HCV proteins [9], with the Mdr2
knockout (Mdr2-KO) mice, a model of inflammation-associated
HCC. The Mdr2-KO mice develop liver tumors in about 100% of
animals by the age of 16 months on the FVB/N genetic
background; initially, this model was generated in the 129/
OlaHsd strain, but due to a low fertility of the resulting mutants,
the Mdr2-KO mutation was transferred into the FVB/N strain
[11,18]. We monitored HCC development in these hybrid mice by
ultrasound, and, upon sacrifice, analyzed mitotic, apoptotic and
gene expression patterns in their tumorous and non-tumorous liver
tissues.
Materials and Methods
Mice
Mice were maintained at the Specific Pathogen-Free (SPF) unit,
Faculty of Medicine, Hebrew University, under a 12 h light/dark
cycle, and provided with food and water ad libitum. All animal
experiments were performed according to national regulations and
guidelines of the Institutional Animal Welfare Committee (NIH
approval number OPRR-A01-5011). Founders of the FVB.129P2-
Abcb4
tm1Bor (Mdr2-KO; old name FVB.129P2-Pgy24
tm1Bor) mice
were purchased from the Jackson Laboratory (Bar Harbor, USA)
[11]. Transgenic mice expressing the whole HCV 1b polyprotein
were kindly provided by Prof. N. La Monica (IRBM, ‘‘P.
Angeletti’’, Pomezia, Italy) [9]. Double Mdr2-KO/HCV-Tg mice
were produced by crossing between homozygous Mdr2-KO and
HCV-Tg mice, and by backcrosses of the resulting F1 hybrid (both
Mdr2- and HCV-heterozygous) with the parental Mdr2-KO
strain. Appearance of tumors was monitored by ultrasound from
the age of 10 months, using an ATL 5000 device (ATL, Bothell,
WA) with linear transducer (12–15 mHz). Mice were sacrificed at
the age of 14 months, when tumor appearance was detected in
most Mdr2-KO mice.
Genotyping
DNA from mouse tails or livers was purified by either the
WizardH Genomic DNA purification kit (Promega, Madison, WI)
or by the PuregeneH DNA isolation kit (Gentra systems,
Minneapolis, MN). Genotype analysis was carried out by PCR
analysis of DNA extracted from mouse tails using HCV transgene,
Mdr2 and Neo primers (primers sequences are specified in the
Table 1).
Harvesting of mouse tissue
Non fasting mice were anesthetized with isoflurane and
sacrificed by cervical dislocation. Livers were rapidly excised and
weighed; a part of the liver was fixed with 4% buffered
formaldehyde for histological analysis, and the remaining tissue
was rapidly frozen in liquid nitrogen and stored at 280uC until
further use.
RNA extraction and analysis
Total RNA was isolated from snap frozen mouse liver tissues
with the TrizolH reagent (Invitrogen, Carlsbad, CA) as described
by the manufacturer. Whole genome gene expression profiling of
RNA samples was performed using Affymetrix GeneChipH Mouse
Exon 1.0 ST Array (Affymetrix, Santa Clara, CA).
Calculation of gene expression values
The raw data were processed by the PartekH Genomics Suite
TM
(Partek GS) (Partek Inc., St. Louis, MO) software. RMA algorithm
was applied for summarization, and the normalization was
performed by the quantile method. The normalized expression
values were processed by the Partek batch removing tool. The
analysis was repeated twice: on ‘‘extended’’ and ‘‘core’’ subsets of
probe-sets and when the probe-set mean was applied for
evaluation of transcript cluster expression level. The processed
data were submitted either to fold-change analysis with a threshold
of 1.85, to hierarchical clustering with the Eisen software [19], or
to SPIN analysis (sorting points into neighborhoods (sorting
algorithm)) [20], which enables arrangement of expression profiles
in the order of similarity (‘‘side-to-side’’ sorting variant).
Analysis of alternative splicing
The alternative splicing calculation was performed using the
definition of splicing index as average log2 transformed relations
between expression levels of individual probe-sets (representing
individual exons) and transcript clusters (evaluation of gene
expression level) [21]. Statistical significance of the differences
between splicing indices in different experimental groups was
evaluated with the ANOVA test for comparison between the non-
matched samples or paired T-test for matched samples (tumors
and non-tumorous tissues). The significant difference in the
splicing index was considered to be a sign of change of the tested
exon inclusion levels. Only probe-sets and transcripts with a
maximal expression level .5 (in log2 scale) were used.
Confirmation of differential gene expression by RT–PCR
Reverse transcription of total RNA was performed using the
MMLV Reverse Transcriptase and random hexamer primers
(Promega, Madison, WI). Semi-quantitative PCR was performed
using Super-therm Taq Polymerase (JMR, UK). For each gene,
Table 1. PCR primers.
Gene Sense primer Antisense primer
HCV transgene 59-ggcgcacatggcatcctc-39 59-gccaccgcaaggtctcgt-39
Mdr2 59-gctgagatggatcttga-39 59-tagccagatgatgg-39
Neo 59- aagaccgacctgtccg-39 59-tattcggcaagcaggcatcg-39
Hprt 59- gttaagcagtacagccccaaa-39 59- agggcatatccaacaacaaactt-39
Gtf3c2 59- ggtgtcacagtggctcaaga-39 59- aatggctgcttggagagaaa-39
Sec24c 59- tccacaacttggccctaaac-39 59- aaaccagctgccgaacatag-39
Cyp4a31 59- acaaggaccttcgtgctgag-39 59- cttgggacaggtgggtagag-39
Erbb4 59- atggccttccaacatgactc-39 59- cacctgccatcacattgttc-39
Esm1 59- gggatggaatgcaaagagac-39 59- agcgttcccttctccaatct-39
Id3 59- gaggagcttttgccactgac-39 59- tgaagagggctgggttaaga-39
Ifrd1 59- tccaagcctcctttcttgtg-39 59- gaccgctgctttctcttgtc-39
Ndrg1 59- tgtcccgagagctacatgac-39 59- ctcttgcaggagaccagtga-39
Nrg1 59- tcggtcagaacgaaacaaca-3 59-tcgtggagtgatgagctgtg-39
Ptgds 59- aaccagtgtgagaccaagatca-39 59- ttggtgcctctgctgaatag-39
Sox4 59- ggcttcctaccttgcaacaa-39 59- tcgattgcagttcacgagag-39
Styk1 59- atggatggcctgctctatga-39 59- caggcccagatgacaaagtt-39
Tff2 59- cttggtgtttccacccactt-39 59- caccagggcacttcaaaga-39
Ubd 59- ggatttccaacccagctactc-39 59- gcagaaggatctggtcctgta-39
Vnn1 59- gggagacaagaagccgtgta-39 59- aacaggtgaagacgccaaac-39
doi:10.1371/journal.pone.0005025.t001
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established in the linear amplification range. Expression levels for
each gene were normalized against one of the following
housekeeping genes: Hprt, Gtf3c2 or Sec24c (PCR primers are
specified in the Table 1). Pictures of agarose gels were taken by
B.I.S. 202D BioImaging System (Amersham Pharmacia Biotech.,
USA). The intensities of bands and p-values were obtained using
the ImageGauge Ver. 4.0 program for quantification of images
(Fujifilm Science Lab.). Real-time PCR was run in triplicates using
the TaqMan Universal PCR Master Mix, primers, probe sets, and
the ABI PRISM 7700 Sequence Detector System from Applied
Biosystems (Foster City, CA). Threshold cycle numbers (Ct) were
determined with the Sequence Detector Software (version 1.6;
Applied Biosystems) and transformed using the DCt method as
described by the manufacturer. The relative quantification values
for each gene were normalized against the endogenous house-
keeping gene Sec24c, which was one of the most uniformly
expressed genes in all RNA samples subjected to global gene
expression profiling. Relative quantitation value of each tumorous
sample was compared to the relative quantitation value of its
matched non-tumorous sample.
Immunohistochemistry
Immunostaining was performed on four-micrometer-thick,
formalin-fixed, paraffin-embedded liver tissue sections by standard
procedures. Antigen retrieval was done with citrate buffer, pH 6.0
(HCV core, b-catenin, galectin-1, and Ubd/Fat10) or glycine
buffer, pH 9.0 (cyclin D1) in a microwave. Primary antibodies
were: anti-HCV-core Ab (ABR Affinity Bioreagents, Golden, CO),
rabbit anti-cyclin D1 SP4 clone (Diagnostic Biosystems, Pleasan-
ton, CA), anti-b-catenin (BD Bioscience, San Jose, CA), anti-
galectin-1 and anti-Ubd/Fat10 (SC-19277 and SC-51086, respec-
tively, both from Santa Cruz biotechnology, Santa Cruz, CA). We
used the SuperPicture
TM-HRP polymer conjugate broad spectrum
kit (Zymed, San Francisco, CA) as secondary antibody for HCV
core and Cyclin D1, EnvisionH+HRP labeled polymer (DAKO,
Carpinteria, CA) for b-catenin, LSABH+System-HRP (Dako,
Carpinteria, CA) for galectin-1, and HRP-conjugated donkey
anti-goat antibody (Jackson ImmunoResearch Laboratories, West
Grove, PA) for Ubd/Fat10 staining. Color development with
diaminobenzidine was done using the Zymed kit as mentioned
above. Scores for galectin-1 staining were assessed according to
evaluation of average level of staining all along the section.
Statistical analysis of the data
Significance of the difference in tumor incidence between
mouse groups was tested by Chi-Square-test; significance of
differences in the levels of blood enzymes, in the levels galectin-1
immunostaining, in the frequency of mitosis and apoptosis, and in
the semi-quantitative RT-PCR was tested by t-test. Statistical
evaluation of differential expression between the experimental
groups was performed using ANOVA test.
Results
Effect of the HCV transgene on hepatocarcinogenesis in
Mdr2-KO mice
The first breeding between homozygous HCV-Tg and Mdr2-
KO mice (having C57Bl/6 and FVB/N genetic backgrounds,
respectively) produced a generation of HCV- and Mdr2-
heterozygotes (Fig. S1). The second backcross of these mice to
the maternal Mdr2-KO strain produced the N2 generation which
contained 25% of the C57Bl/6 genetic background. We continued
to produce backcrosses till the N7 generation, an incipient
congenic strain containing only 0.8% of the donor C57Bl/6
genetic background and 99.2% of the recipient FVB/N genetic
background. The produced hybrid mice were followed for HCC
development, and comparison between the N2 and N7 genera-
tions was performed. Independently of the presence of the HCV
transgene, Mdr2
+/2 mice did not develop HCC upon sacrifice at
18 months of age, whereas all Mdr2-KO mice did produce liver
tumors at 14 months of age (Table 2). Most tumors were well-
differentiated HCC as determined by previously described criteria
[18] and by immunostaining for reticulin fibers (not shown).
Immunohistochemical analysis of liver tissues from HCV-Tg mice
with antibodies to the core protein showed non-uniform
distribution of HCV transgene expression both in Mdr2-KO
and Mdr2-heterozygous mice. Levels of the HCV transgene
expression were similar between Mdr2-KO/HCV-Tg mice from
the N2 and N7 generations (Fig. 1, A and B). However, a
significant difference in the incidence of large tumors was observed
upon comparing N2 female mice with and without the HCV
transgene: only N2 female mice with the HCV transgene had
tumors with diameters over 1 cm (p=0.0445; Table 2 and
Fig. 1C). In contrast, in mice from the N7 generation, the
incidence of large tumors was independent of the presence of the
HCV transgene and was similar to that in Mdr2-KO/HCV-Tg
mice from the N2 generation. The 25% of the C57Bl/6 genetic
background present in the N2 generation had a tumor suppressive
effect in the Mdr2-KO mice not having the HCV transgene
(Fig. 1C). There was a statistically significant reduced incidence of
tumors with a diameter over 1 cm between the animals from the
N2 and N7 generations (Chi-Square-tests for both all mice
(p=0.0237) and for females (p=0.0299); Table 2). The tumor
promoting effect of the HCV transgene was statistically significant
only on the partially suppressive N2 genetic background, and only
in females (p=0.0445).
Higher levels of liver enzymes (alanine aminotransferase,
aspartate aminotransferase and alkaline phosphatase) were found
in the serum of all Mdr2-KO mice compared to Mdr2
+/2 controls
(Fig. 2A), as expected [15]. However, the only statistically
significant difference between Mdr2-KO/HCV mice and Mdr2-
KO mice from the N2 generation was in the level of alkaline
phosphatase, found in females only (p=0.04). Nevertheless, there
was no direct correlation between the level of alkaline phosphatase
and liver tumor load/incidence in individual Mdr2-KO/HCV
mice. Similarly, high levels of serum liver enzymes were also
measured in Mdr2-KO mice of the N7 generation; however, the
level of alkaline phosphatase was not specifically increased in the
Mdr2-KO/HCV-Tg females compared to Mdr2-KO females not
expressing the HCV transgene (Fig. 2B).
Effect of the HCV transgene on mitosis and apoptosis in
Mdr2-KO mice
To investigate the potential mechanisms for the effect of the
HCV transgene on hepatocarcinogenesis, we compared mitotic
and apoptotic events in non-tumorous and tumorous liver tissues
of the Mdr2-KO and Mdr2-KO/HCV-Tg females from the N2
and N7 generations (Fig. 3A – mitosis, Fig. 3B - apoptosis) and of
the males from the N2 generation (Fig. 3C). Interestingly, we
observed a statistically significant decrease of mitosis (p,0.016)
and apoptosis (p,0.002) in the non-tumorous tissues of the Mdr2-
KO/HCV-Tg females from the N2 generation only; however,
once the anti-mitotic effect of the HCV transgene was bridged in
tumors, then mitosis was enhanced in both female and male mice
from the N2 generation (Fig. 3A and Fig. 3C). This effect was
more prominent in female mice, although it did not reach
statistical significance. The presence of the highly proliferative
HCV Tumor Promoting Effect
PLoS ONE | www.plosone.org 3 April 2009 | Volume 4 | Issue 4 | e5025Figure 1. HCV transgene expression and incidence of large liver tumors in female mice from the N2 and N7 generations. (A) Similar
expression levels of the HCV transcript in 14-month-old Mdr2-KO/HCV mice from the N2 and N7 generations. Average levels of the HCV transcript
were determined by semi-quantitative RT-PCR relative to expression level of the housekeeping gene Hprt in 5 females from the N2 generation and in
15 females from the N7 generation. (B) Similar expression of the HCV core protein in 14-month-old Mdr2-KO/HCV mice from the N2 and N7
generations. Representative immunohistochemical staining against HCV core protein in females from the N2 and N7 generations (magnification:
6200). (C) Higher incidence of large liver tumors (diameter over 1 cm) per mouse in 14-month-old Mdr2-KO/HCV compared to Mdr2-KO female mice
from the N2, but not from the N7 generations. Incidence of all tumors is shown in Table 2. Red bars – Mdr2-KO/HCV group, blue bar – Mdr2-KO
group.
doi:10.1371/journal.pone.0005025.g001
Table 2. Incidence of HCC in 14-month-old Mdr2-KO/HCV-Tg and Mdr2-KO mice from the N2 and N7 generations.
Incidence of HCC in N2 Tumor size: .1.2 cm Tumor size: 1–1.2 cm Tumor size: 0.8–1 cm Tumor size: 0.5–0.7 cm
genotype sex No. of mice
MDR2-KO/HCV m1 6 1 1 1 5
f1 3 2 3 0 1
a l l 2 9 3416
MDR2-KO m1 0 0 1 0 3
f 8 0013
a l l 1 8 0116
Incidence of HCC in N7 Tumor size: .1.2 cm Tumor size: 1–1.2 cm Tumor size: 0.8–1 cm Tumor size: 0.5–0.7 cm
genotype sex No. of mice
MDR2-KO/HCV m 1 3 0124
f 1 6 4253
all 29 4 3 7 7
MDR2-KO m 1 2 2105
f 1 4 5132
all 26 7 2 3 7
doi:10.1371/journal.pone.0005025.t002
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females indicates a possible reason for the appearance of large
tumors with diameters over 1 cm in this experimental group
(Fig. 1C) as well. In the N7 females, the anti-mitotic effect of the
HCV transgene on non-tumorous liver tissue was absent, and the
mitotic activities of tumors in the Mdr2-KO and Mdr2-KO/
HCV-Tg females were similar to each other and to those of the
Mdr2-KO females from the N2 generation (Fig. 3A). The levels of
apoptosis in tumors were similar between N2 and N7 females,
independent of the presence of the HCV transgene (Fig. 3B).
Gene expression profiling analysis
In an effort to delineate the molecular mechanisms associated
with the tumor promoting effect of the HCV transgene in Mdr2-
KO/HCV-Tg N2 females, we performed a genome scale gene
expression profiling on livers of 14-month-old female mice. Non-
tumorous liver tissues of Mdr2-KO, Mdr2
+/2, Mdr2
+/2/HCV-
Tg, and Mdr2-KO/HCV-Tg female mice from the N2 genera-
tion, as well as all large tumors (diameters over 1 cm) of Mdr2-
KO/HCV-Tg females, were analyzed (Fig. 4). In hierarchical
clustering, the Mdr2 genotype and the tumor phenotype were
major clustering forces separating the samples into three main
clusters: Mdr2-KO, Mdr2
+/2 and tumors. Remarkably, in the
cluster of healthy Mdr2
+/2 mice, the HCV transgene was a
destabilizing factor, whereas in the chronically inflamed Mdr2-
KO background, it was a stabilizing factor providing clusterization
of all HCV-Tg samples into one subcluster. Similarly, Mdr2-KO
mutation was the main factor contributing to the alternative
splicing between the experimental groups (Table S1). Overall, the
contribution of the HCV transgene in both differential gene
expression (Fig. S2) and alternative splicing (Table S1) was only
marginal. However, supervised analysis of genes with a tendency
to differential expression between Mdr2-KO and Mdr2-KO/
HCV-Tg samples revealed a substantial overlap of pathways
affected by the HCV transgene and the Mdr2-KO mutation
(Table S2). This overlap is comprised of all arms of the immune
system, including the innate, humoral and, to some extent, the
adaptive responses; many of these genes were also similarly
differentially expressed between Mdr2
+/2 and Mdr2
+/2/HCV-Tg
samples (data not shown).
Confirmation of differential gene expression
Differential expression of selected genes was further confirmed
by RT-PCR (Table 3). These genes are involved in the regulation
of immune/inflammatory response (Lgals1, Ptgds, Tff2, Ubd),
tumor angiogenesis (Lgals1, Esm1, Ndrg1), epidermal growth
factor signaling (Erbb4, Nrg1), response to tissue injury (Tff2,
Vnn1), and gene transcription (Id3, Ifrd1). Some of these genes
(Lgals1, Nrg1, Ubd) have been already identified previously as
HCV-dependent [22–25]. More detailed information on the
confirmed genes and their potential roles in carcinogenesis can be
found in Table 3.
Up-regulation of two proteins, galectin-1 (encoded by the Lgals1
gene) and diubiquitin (encoded by the Ubd/Fat10 gene), was
confirmed by immunohistochemistry. Galectin-1 modulates innate
and adaptive immune responses; its over-expression in many types
of tumors and/or surrounding tissues promotes tumor progression
by inhibition of anti-tumor immune response [26]. Galectin-1 was
overexpressed in non-tumorous liver tissue of Mdr2-KO/HCV-
Tg mice, mostly in the cytoplasm of hepatocytes in zones 1 and 3,
in endothelial cells, and on the luminal side of cholangiocyte
membranes (Fig. 5). Diubiquitin is involved in the maintenance of
spindle integrity during mitosis and is highly upregulated in
human HCC [27]; it was detected mostly in the cytoplasm of
hepatocytes in the tumors of Mdr2-KO/HCV-Tg mice, and, to a
lesser degree, in non-tumorous liver tissues of Mdr2-KO mice with
or without the HCV transgene (Fig. 6). Remarkably, diubiquitin
was detected in the hepatocyte nuclei only in large tumors of
Mdr2-KO/HCV-Tg mice, similar to its nuclear localization in
human HCC [27].
Testing of other known effects of the HCV transgene
expression
We searched for a correlation between the local level of the
HCV transgene expression (revealed by immunohistochemical
Figure 2. Levels of liver enzymes in the serum of 14-month-old Mdr2-KO female mice. Liver enzymes: Alkaline Phosphatase (ALP) Alanine
aminotransferase (ALT), and Aspartate aminotransferase (AST) were measured in serum of 14 month old female mice. Graph represents average levels
6SD. (A) Comparison of enzymes levels (U/l) between Mdr2-KO and Mdr2
+/2 with and without HCV-Tg from the N2 generation. (B) Comparison of
enzymes levels (U/l) of Mdr2-KO/HCV and Mdr2-KO females from N2 and N7 generation. Statistically significant difference was found in ALP levels
between Mdr2-KO/HCV females and Mdr2-KO females of the N2 generation only (* p=0.04).
doi:10.1371/journal.pone.0005025.g002
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There was no correlation between the level of HCV transgene
expression and the presence of dysplastic nodules in Mdr2-KO/
HCV-Tg mice. It was shown previously that HCV-associated
HCC is characterized by increased frequency of b-catenin
mutations and by activation of b-catenin signaling [28,29]. We
reported recently that in the non-tumorous liver of Mdr2-KO
mice, b-catenin signaling is inhibited while the nuclear level of
cyclin D1 is increased [18]. The expression level of the HCV
transgene in hepatocytes of Mdr2-KO/HCV-Tg mice correlated
neither with the nuclear level of cyclin D1 nor with the
cytoplasmic/nuclear level of b-catenin (a typical example shown
in Fig. 7A). However, in some rare cases, high HCV transgene
expression correlated with nuclear localization of b-catenin
(Fig. 7B). One of the six tumors analyzed by whole genome gene
expression profiling was characterized by a prominent upregula-
tion of the b-catenin-activated genes and by rare scattered b-
catenin-positive hepatocyte nuclei (data not shown).
Discussion
The molecular mechanisms of HCV-induced HCC develop-
ment are still not well understood; one of the main questions is
whether HCC develops due to chronic inflammation or whether
HCV proteins are endowed with some oncogenic activity.
Multiple cell culture models have demonstrated the oncogenic
potential of several HCV proteins; however, most transgenic
mouse models expressing HCV proteins did not develop HCC [2].
Similarly, none of the two previously generated transgenic mouse
models expressing the whole HCV polyprotein is developing HCC
[7,9,10]. Taking into account that in mouse transgenic models
there is no host immune reaction against expressed viral proteins,
we explored whether HCV proteins would accelerate inflamma-
tion-associated hepatocarcinogenesis. We bred mice expressing the
whole HCV polyprotein with Mdr2-KO mice, a model of
inflammation-associated HCC, and monitored HCC development
in two generations of hybrid mice: N2 and N7, containing 25%
and 0.8% of C57Bl/6 genetic background, respectively. We
demonstrated, for the first time, that a transgene expressing the
whole HCV polyprotein accelerates inflammation-associated
hepatocarcinogenesis in vivo in a host genetic background-
dependent manner: only in the N2 generation and only in
females. Remarkably, our previous studies of Mdr2-KO mice [15]
demonstrated that chronic liver disease at an early precancerous
stage in this HCC model shares many features characteristic of
chronic HCV infection and HCV-induced cirrhosis in patients:
hepatocyte G1 arrest and up-regulation of genes Mcm2 [30],
Cxcl9, Lgals3, Iqgap1, Lum, Col6a3, Igfbp7, Vim, Ablim, Mpp1
Figure 3. Mitotic and apoptotic events in the livers of mice from the N2 and N7 generations. Events were counted per 50 HPF 6SD in
H&E stained liver sections of tumors (0.3–1 cm diameter) and non-tumorous tissue samples from 14-month-old mice. (A) Reduced mitotic events
(p=0.016) in non-tumorous liver tissues of Mdr2-KO/HCV females compared to Mdr2-KO female mice from the N2, but not from the N7 generations.
(B) Reduced apoptotic events (p=0.002) in non-tumorous liver tissues of Mdr2-KO/HCV females compared to Mdr2-KO female mice from the N2, but
not from the N7 generations. (C) Similar intensities of mitotic and apoptotic events in the livers of male mice from the N2 generation. There was no
statistically significant difference between groups.
doi:10.1371/journal.pone.0005025.g003
HCV Tumor Promoting Effect
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confirmed by a significant overlap of pathways affected by the
HCV transgene and the Mdr2-KO mutation revealed in the
current study (Table S2).
The 25% of C57Bl/6 genetic background had a tumor-
suppressive effect on HCC development in the N2 mice not
having the HCV transgene, in accord with a well known low
susceptibility of the C57Bl/6 mice to tumors [33]. Thus, in the
PyMT mouse model of breast cancer, C57Bl/6 mice and F1
hybrids between the C57Bl/6 and FVB/N strains had more
prolonged primary tumor latency than the FVB/N mice [34,35].
Remarkably, the effect of inducible nitric oxide synthase deficiency
on mammary tumor development and metastasis was prominent
in the C57Bl/6 genetic background, where tumors developed
slowly, but was not observed in the FVB/N genetic background,
where tumors developed quickly [34]. In the Ras-induced skin
squamous carcinoma model, the low susceptibility of the C57Bl/6
strain and the high susceptibility of the FVB/N had been
attributed to a polymorphism in the Ptch gene [36]. Interestingly,
it was recently demonstrated that inactivation of the Nox2 gene in
the mutant Sod1 mouse model for amyotrophic lateral sclerosis
significantly increased survival when mice were of mixed genetic
background [37], but had very modest effect on the inbred C57Bl/
6 strain [38]. In accord with these findings, our data demonstrate
that for mouse models of human diseases, a specific genetic
Table 3. Confirmation of the differential gene expression by RT-PCR.
Gene symbol Accession number
Differential
expression
$ Ttest
& Gene name
Known or suggested role of the
gene in cancer
Cyp4a31
@ NM_201640 KO.NT p=0.001 Cytochrome P450, family 4,
subfamily a, polypeptide 31
Iron ion binding [49].
Erbb4
@ NM_010154 T.NT p=0.003 V-erb-a erythroblastic leukemia viral
oncogene homolog 4
Activated by neuregulins; increases
proliferation potential of cancer cells [50].
Esm1
@ NM_023612 T.NT p=0.009 Endothelial cell-specific molecule 1 Preferentially expressed in tumor
endothelium [51].
Gnmt
# NM_010321 T,NT Glycine N-methyltransferase Downregulated in HCC [52].
Id3
@ NM_008321 T,NT p=0.04 Inhibitor of DNA binding 3 Expression in HCC decreases with tumor
dedifferentiation [53].
Ifrd1
@ NM_013562 T.NT p=0.04 Interferon-related developmental
regulator 1
Regulates differentiation of epithelial cells
[54].
Ndrg1
@ NM_008681 T.NT p=0.02 N-myc down-stream regu-lated
gene 1
Mediates prolife-ration and invasion of
HCC cells [55].
Nrg1
@ NM_178591 T.NT p=0.006 Neuregulin 1 Upregulated in HCV-induced HCC [24].
Ptgds
@ NM_008963 KO,NT p=0.04 Prostaglandin D2 synthase Antiproliferative in prostate cancer [56].
Sox4
@ # NM_009238 KO.NT p=0.003 SRY-box containing gene 4 Positive regulator of HCC cells’ apoptosis
[57].
Styk1
@ NM_172891 T.NT p=0.006 Serine/threonine/tyrosine kinase 1 Induces tumorige-nesis and metastasis in
nude mice [58].
Tff2
@ NM_009363 KO,NT p=0.02 Trefoil factor 2 Promotes epithelial-cell restitution, cont-
rols inflammation and systemic immune
responses [59].
Ubd
@ NM_023137 T.NT p=0.03 Ubiquitin D (FAT10) Upregulated in various cancers including
HCC [27], resulting in chromo-some
instability [60].
Vnn1
@ NM_011704 T.NT p=0.01 vanin 1 Regulates response to oxidative injury in
epithelial cells [61].
@Confirmed by semi-quantitative RT-PCR.
#Confirmed by real time RT-PCR (Sox4 was confirmed by both methods).
$T – tumorous and NT – matched non-tumorous liver tissues of Mdr2-KO/HCV-Tg females; KO - non-tumorous liver tissues of Mdr2-KO females.
&p-values for semi-quantitative RT-PCR are provided (see ‘‘Materials and methods’’).
doi:10.1371/journal.pone.0005025.t003
Figure 4. Hierarchical clustering of expression profiles of liver
tissue samples subjected to whole genome expression profil-
ing. Average linkage hierarchical clustering of liver tissue samples from
females of the N2 generation was performed on 5,000 genes with
highest STD values using the software from Michael Eisen’s Laboratory
(Lawrence Berkeley National Laboratory and University of California,
Berkeley; http://rana.lbl.gov/EisenSoftware.htm). The Mdr2 genotype
and the tumor phenotype were major clustering forces, whereas the
contribution of the HCV transgene in clustering was only marginal.
doi:10.1371/journal.pone.0005025.g004
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and/or therapeutic treatments will be the most prominent.
The female-specific effect of the HCV transgene raises a
question about the relevance of this model to human disease, since
it is widely accepted that human HCC is more prevalent in males.
The typical average ratio of males:females among HCC patients is
3:1 [39], however, this proportion depends on the etiology of the
disease: among HBV-infected patients, it is about 6:1, whereas
among HCV-infected patients, it is about 1.7:1 [40]. Moreover,
when other higher HCC risk factors in males such as alcohol
consumption are taken into account, the normalized risk of HCC
among HCV-infected patients may be higher for females [41].
Therefore, the appearance of the tumor-promoting effect of the
HCV transgene seen only in females in the described model may
have a physiological significance. Recently, it was demonstrated
that in chemically induced hepatocarcinogenesis in C57Bl/6 mice,
the estrogen-mediated inhibition of IL-6 production is responsible
for a lower risk of liver cancer in females [3]. However, in the
Mdr2-KO mice, the risk for liver cancer is similar in both genders
[11,42], suggesting that there are probably other mechanisms
regulating hepatocarcinogenesis in this model of chronic inflam-
mation-associated HCC.
Comparison of mitotic and apoptotic events in non-tumorous
liver tissues of the Mdr2-KO and Mdr2-KO/HCV-Tg mice
revealed a statistically significant decrease of mitosis and apoptosis
in the Mdr2-KO/HCV-Tg females from the N2 generation.
Interestingly, similar effects of the transgene expressing the HCV
open reading frame on the untransformed human hepatocytes
have been demonstrated recently: absence of the direct oncogenic
activity, inhibition of cell proliferation, and up-regulation of genes
involved in innate immune response/inflammation [43]. Howev-
er, in tumors, an inverse tendency took place: Mdr2-KO/HCV-
Tg mice had higher levels of both mitosis and apoptosis, whereas
in Mdr2-KO mice, the levels of mitosis and apoptosis in non-
tumorous and tumorous tissues were similar. These findings
suggest that the accelerating effect of the HCV transgene on
hepatocarcinogenesis in this model is most probably due to
promotion of tumor proliferation by the HCV transgene.
Similarly, the difference in liver cancer susceptibility between the
C3H/He and C57Bl/6 strains has been attributed to a dissimilar
tumor cell proliferation between these two groups, but not to
intensity of apoptosis in their livers [44]. High standard errors
observed in the current study for many parameters at the
tumorous stage of the disease (e.g., hepatocyte’s apoptotic and
mitotic frequencies) were most probably caused by a prolonged
Figure 5. Higher expression of galectin-1 in the livers of Mdr2-KO/HCV-Tg N2 females. (A–C) Immunohistochemical staining of non-
tumorous liver tissues of 14-month-old Mdr2-KO and Mdr2-KO/HCV-Tg females from N2 generation with an antibody specific to galectin-1. (A) Left
panel: Mdr2-KO/HCV-Tg; right panel: Mdr2-KO females. Magnification: upper panel640, lower panel6100. (B) Cytoplasmic staining of hepatocytes in
Mdr2-KO/HCV livers. Magnification 6400. (C) Staining of luminal side of cholangiocytes’ membranes (indicated by arrows) in Mdr2-KO/HCV livers.
Magnification6400. (D) Scores of the immunostaining level for all liver samples in each group are shown in blue circles; average scores of each group
are shown in red squares; p=0.007 between the groups.
doi:10.1371/journal.pone.0005025.g005
Figure 6. Nuclear expression of diubiquitin in tumors and its
cytoplasmic expression in non-tumorous hepatocytes. Immu-
nohistochemical staining of 14-months-old Mdr2-KO/HCV-Tg N2
females with an antibody specific to diubiquitin. (A) Nuclear staining
of hepatocytes in tumorous tissue (arrows). (B) Cytoplasmic staining of
hepatocytes in non-tumorous liver tissue (arrows). Magnification:6400.
doi:10.1371/journal.pone.0005025.g006
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homeostatic mechanisms in the mutant mice.
The tumor promoting effect of the HCV transgene may be
explained both by upregulation of pro-tumorigenic genes as Ubd,
Erbb4,Nrg1,Ndrg1,Styk1(Table 3),and byevasionofhostdefense
response by viral proteins [45,46]. Over-expression of the galectin-1
protein in the liver of Mdr2-KO/HCV-Tg mice may also cause
inhibition of anti-tumor immune response [26]. One of the known
differences between the C57Bl/6 and FVB/N inbred strains is that
thelatterisC5complement-deficient. Theimportant role ofC5and
its receptor C5a in host inflammatory reactions [47] suggests that
this factor may be responsible for the observed differences in HCC
development between the N2 and N7 generations. Interestingly,
comparison of differentially expressed genes (Mdr2-KO relative to
control mice) of the N2 generation and of FVB/N Mdr2-KO mice
aged 12months[15] or16months[18],previouslypublishedbyour
group, revealed significant up-regulation of the complement
component C9 in the Mdr2-KO livers of the N2 generation (4-
fold; p=0.0066), but not in FVB/N Mdr2-KO mice. And
conversely, inflammatory markers Aif1, Cd36, Cd44 and Spp1
(osteopontin) were up-regulated in FVB/N Mdr2-KO mice at all
tested ages, but not in the Mdr2-KO livers of the N2 generation.
This study demonstrates that the HCV transgene accelerated
inflammation-associated hepatocarcinogenesis in vivo in a host
genetic background-dependent manner, thus emphasizing the
significance of the host genotype in HCV manifestations. This
accelerating effect was prominent in the mixed, partially tumor-
suppressive, FVB/N6C57Bl/6 genetic background, and is most
probably due to promotion of tumor proliferation by the HCV
transgene. Despite multiple reports on the direct oncogenic
activities of different HCV proteins in vitro, in mouse models in
vivo, these data are contradictory, whereas data on the tumor
promoting effect of HCV proteins are much more consistent
[10,23,48]. Our data suggest that the selected Mdr2-KO mouse
model was appropriate for this specific investigation aimed to
determine which of the potential different factors contributed
mainly to HCC development with special emphasis on the
inflammatory process in the Mdr2-KO mice lacking the HCV
transgene as its main contribution to the model. The role of
specific factors contributing to tumor promoting activity of the
HCV transgene: sex, known genes that differ between the two
studied mouse strains, and differentially expressed regulatory genes
revealed by our gene expression profiling analysis requires further
investigation.
Supporting Information
Figure S1 Scheme of the breeding of B6/HCV and Mdr2-KO
mice to generate Mdr2-KO/HCV-Tg mice.
Found at: doi:10.1371/journal.pone.0005025.s001 (1.53 MB TIF)
Figure S2 The effect of Mdr2-KO, HCV-Tg and tumor
phenotype on differential gene expression between experimental
groups. The result of the SPIN analysis performed on 1,000 genes
with the highest standard deviation. The left panel displays the
color-coded standardized Euclidean distance matrix of samples
and the right panel - the expression matrix of genes. Similar to
hierarchical clustering (Figure 4), clustering was determined
mainly by the Mdr2 genotype and the tumor phenotype, whereas
the contribution of the HCV transgene was only marginal.
Found at: doi:10.1371/journal.pone.0005025.s002 (3.16 MB TIF)
Table S1 The effect of Mdr2-KO, HCV-Tg, and tumor
phenotype on alternative splicing. Numbers before slash represent
the amount of probe-sets with 2-fold or 1.8-fold change in the
relative level of exon inclusion, determined as statistically
significant by either paired t-test (for tumors versus non-tumorous
tissues), or two-way ANOVA (for all other categories). Numbers
Figure 7. Immunohistochemical detection of the HCV core, b-catenin and cyclin D1 proteins in the liver of Mdr2-KO/HCV-Tg mice.
(A) A typical example of the absence of correlation between the expression of the HCV core and either nuclear level of cyclin D1, or cytoplasmic/
nuclear level of b-catenin proteins in hepatocytes. Magnification:6100. Inserts contain the framed regions magnified6400. (B) A rare example of the
correlation between the expression of the HCV core and nuclear level of b-catenin proteins in hepatocytes (first two panels; magnification: 6200).
Third panel: a typical membrane-associated pattern of b-catenin expression in hepatocytes of Mdr2-KO/HCV-Tg mice. Magnification: 6400.
doi:10.1371/journal.pone.0005025.g007
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the selected probe-sets. * The data for alternative splicing in
tumors could not be directly compared with other categories due
to the use of a different method of calculation.
Found at: doi:10.1371/journal.pone.0005025.s003 (0.03 MB
DOC)
Table S2 Substantial overlapping of pathways affected by the
HCV transgene and by the Mdr2-KO mutation. The SPIN
analysis of the complete set of samples performed in the space of
the 1,000 most variable genes resulted in separation of the samples
into 3 groups: non-tumorous Mdr2-KO, Mdr2(+/2), and
tumorous Mdr2-KO/HCV-Tg samples (Fig. S2, left). The non-
tumorous Mdr2-KO set was roughly separated into Mdr2-KO/
HCV-Tg and Mdr2-KO subsets. The SPIN analysis of the
selected gene-set in the space of all Mdr2-KO samples enabled
isolation of genes with tendency to differential expression between
HCV-Tg and non-HCV samples. The lists of genes with tendency
to up- and down-regulation in Mdr2-KO/HCV-Tg samples were
submitted to functional analysis by GO categories using the
DAVID tool. These results were compared to the results of
functional analysis by GO categories of genes differentially
expressed between Mdr2-KO and Mdr2(+/2) non-HCV samples
(threshold 1.85). For each enriched GO term, the number of
related genes, their percent in the analyzed gene list and the
significance of the enrichment are shown.
Found at: doi:10.1371/journal.pone.0005025.s004 (0.03 MB
DOC)
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